Bionomics Phase II Trial Affirms Renal Cancer Marker For Best Treatment
This article was originally published in PharmAsia News
Australia's Bionomics reports a mid-stage trial of its BNC105 drug for renal cancer has enabled researchers to identify biomarkers pointing to the proper treatment for members of subgroups with the disease.
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 24 November.
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.